ClinicalTrials.gg
CompletedNCT03495167Updated Nov 16, 2022

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

A Phase 1 interventional study of SyB C-1101 in Myelodysplastic Syndrome, sponsored by SymBio Pharmaceuticals. Completed at 9 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-11-16.

Sponsored by SymBio Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies testing ON 01910 in Myelodysplastic Syndromes — none open to participants now, none under way, none of them phase 3. ON 01910 · Myelodysplastic Syndromes.

Enrollment
12th of 17
10 · median 22
Started
2017
the only one that year
Phase 1
8 of 17
none open now
Registered
17th of 17
by date
Lead sponsor
4 of 17
SymBio Pharmaceuticals

Among the 17 studies testing ON 01910 in Myelodysplastic Syndromes, this one is the 12th largest by enrollment, is the only one that started in 2017, is one of 8 in phase 1, and was the 17th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 323 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 17 studies testing ON 01910 in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →

About ON 01910

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing ON 01910 in Myelodysplastic Syndromes as a file.
02

Study summary

To assess tolerability of SyB C-1101 when administered orally BID for 21 days followed by a 7-day observation period in patients with recurrent/relapsed or refractory myelodysplastic syndrome in order to determine a recommended dose (RD). To assess safety, efficacy and pharmacokinetics.

03

Conditions studied

  • Myelodysplastic Syndrome
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients who meet all of the following criteria are eligible for enrollment in the study:

  1. or cytologically diagnosed as myelodysplastic syndrome (MDS) according to WHO criteria or FAB classification. For patients with RAEB in transformation (RAEB-t), peripheral WBC is ≦25,000 /mm3 and the disease is stable for at least 4 weeks.
  2. Classified as Intermediate-1, Intermediate-2 or High-risk, according to IPSS classification.
  3. Patients with a history of previous treatment of the target disease (e.g., therapy, protein anabolic steroids, and chemotherapy including azacitidine and lenalidomide) and meet one of the followings:

    • Patients who failed to achieve complete remission, partial remission, or hematologic improvement*
    • Patients experienced with recurrence/relapse after achieving complete remission, partial remission, or hematologic improvement*
    • Patients who were intolerable to the previous therapy *: The most recent assessment of the therapeutic effect based on "Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia" (IWG2006 criteria)
  4. Off all other treatment (including erythropoiesis stimulating agents) for MDS, for at least 4 weeks prior to enrollment and no carry-over (of antitumor effect) from previous treatment is expected as judged by Investigator. Transfusion is allowed, as clinically indicated.
  5. Patients with expected survival of ≥3 months.
  6. Patients aged 20 years or older (at the time of ).
  7. Performance Status (PS) of 0, 1 or 2
  8. Patients with adequate major organ functions (including the heart, lungs, liver, and kidneys).

    • (GOT): ≤2.5 -fold the at each institution
    • ALT (GPT) : ≤2.5 -fold the upper limit of normal range at each institution
    • Total : \<2.0 mg/dL (except patients with Gilbert's disease or hemolysis)
    • Serum creatinine: \<2.0 mg/dL
    • : Absence of abnormal findings that require treatment
    • Echocardiography: Absence of abnormal findings that require treatment
  9. The patient must sign an informed consent form indicating that s/he understands the purpose of and procedure required for the study and is willing to participate in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    SyB C-1101

    Drug: SyB C-1101

Interventions

  • SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice daily (840 mg before breakfast and 280 mg before dinner. SyB C-1101 will be administered orally twice daily for 21 consecutive days, followed by a 7-day observation period. The treatment period of 28 days (21 days of administration + 7 days of observation) constitutes 1 cycle.

06

What researchers measure

Primary outcomes

  1. Identification of Dose-Limiting Toxicity (DLT) and Number of Patients with DLT in Each Cohort

    Based on the number of patients with DLT and administration dose in each cohort, recommended dosage will be defined for the following clinical phase. A DLT is defined as an adverse event that occurred during the Cycle 1, for which a causality with the investigational products (IP) cannot be ruled out and meets the following criteria. Criteria: ≥ Grade3 non-hematological toxicity (except pyrexia). However nausea, vomiting, diarrhea, stomatitis and esophagitis/dysphagia are excluded (≥ Grade 3 nausea, vomiting, and diarrhea persist for ≥ 48 hours and uncontrolled by antiemetic or antidiarrheal agents, and ≥ Grade 3 stomatitis and esophagitis/dysphagia lasting for ≥ 4 days are regarded as DLTs). ≥ Grade 2 pyrexia uncontrolled by antipyretic agents. However, in case pyrexia of ˃ 39°C occurred within 24 hours after administration of SyB C-1101 and its cause is unclear, it is deemed that the causality to the IP cannot be ruled out.

    Time frame: Up to 2 years

Secondary outcomes

  1. Incidence of adverse events

    Calculate from the rate between number of patients occurred AE and number of patients received SyB C-1101.

    Time frame: Up to 2 years

  2. Severity of adverse events

    Score as grade 1 to 5 according to criteria by CTCAE v4.0-JCOG.

    Time frame: Up to 2 years

  3. Relationship of adverse events to SyB C-1101

    Score as "related " or "not related".

    Time frame: Up to 2 years

  4. Change of laboratory test values

    Number of patients with changes in laboratory values OR list each lab value separately (e.g.Hgb, Fe, Hct, etc.)

    Time frame: Up to 2 years

  5. Overall hematologic response rate

    Calculate from the rate of patients scored as CR, PR or marrow CR according to IWG 2006 criteria.

    Time frame: Up to 2 years

  6. Overall hematologic improvement rate

    Calculate from the rate of patients with hematologic improvement according to IWG 2006 criteria.

    Time frame: Up to 2 years

  7. Overall cytogenetic response rate

    Calculate from the rate of patients scored as complete cytogeneic response or partial cytogenetic response according to IWG 2006 criteria.

    Time frame: Up to 2 years

  8. Cmax

    Maximum plasma concentration

    Time frame: Up to 2 years

  9. tmax

    Time to maximum plasma concentration

    Time frame: Up to 2 years

  10. AUC

    Area under the plasma concentration curve

    Time frame: Up to 2 years

  11. t 1/2

    Half-life time

    Time frame: Up to 2 years

07

Study locations

9 sites
  • Research Site
    Nagoya, Aichi, Japan
  • Research Site
    Maebashi, Gunma, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Kobe, Hyogo, Japan
  • Research Site
    Kurashiki, Okayama, Japan
  • Research Site
    Shinagawa, Tokyo, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Kumamoto, Japan
  • Research Site
    Kyoto, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in May 2019, 19 months.

Of 84 industry-sponsored phase 1 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 19 months is below that.

Counting every sponsor, half of 220 studies reached it within 52 months; a quarter within 31 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2017
First posted
Apr 11, 2018
StartActual
Oct 6, 2017
Primary completionActual
May 28, 2019
CompletionActual
May 28, 2019
Last update
Nov 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03495167
Responsible party
Sponsor
First posted
Apr 11, 2018
Start date
Oct 6, 2017
Primary completion
May 28, 2019
Completion
May 28, 2019
Last update
Nov 16, 2022

Study contacts

Katsuhisa Goto
study director · SymBio Pharmaceuticals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ON 01910

Start the discussion